Anlotinib sells 4 billion yuan. How can China's biopharmaceuticals rise to a market value of 150 billion yuan?

In the 2020 financial report of China Biopharmaceuticals, the oncology business has resisted the performance banner for the first time and has become the highest sales area.

01 For the first time, the oncology business "carried the banner"

On March 23, Sino Biopharmaceutical released its 2020 financial report.

The financial report shows that China Biopharma's annual revenue was 23.

The products of China Biopharmaceutical mainly involve liver disease, anti-tumor, orthopedics, anti-infection and respiratory system drugs, of which anti-tumor drugs are the most core field.

Source: Insight database

It is worth noting that, with the successive launch of anti-tumor products, the anti-tumor field will become the treatment field with the largest proportion of China's biopharmaceutical sales in 2020 for the first time.

From a longitudinal point of view, the former "ace" field of liver disease has been declining.

In terms of research and development, the research and development model of "independent research and development + external mergers and acquisitions + license introduction" used by established pharmaceutical companies is also a transformation method of China's biopharmaceutical industry.

In addition to Anlotinib, the pipeline of China Biopharmaceuticals also includes 31 new small molecule drugs.

In terms of investment, China Biopharmaceuticals is also similar to most established pharmaceutical companies.

It is reported that in December 2020, China Biopharmaceutical invested US$515 million in Kexing Zhongwei and obtained 15.

In 2020, CP Tianqing cooperated with Kangfang Biotechnology to develop and commercialize PD-1 Paimrizumab and obtained the FDA rapid review channel qualification.

On the same day the financial report was released, China Biopharmaceuticals also issued an M&A announcement.

In fact, it is not difficult to see that in the transformation of most established pharmaceutical companies, centralized procurement is a factor that cannot be underestimated.

02 Volume procurement forced transformation

At the end of 2018, the "4+7" centralized procurement was expanded in September 2019.

The failure of generic drugs and the dividends of innovative drugs, the development direction of China's biopharmaceuticals can be imagined.

The roller coaster-like stock price and market value changes also show the dividends that innovative drugs bring to China's biopharmaceuticals.